Article | Published:

A homozygous founder missense variant in arylsulfatase G abolishes its enzymatic activity causing atypical Usher syndrome in humans

Genetics in Medicinevolume 20pages10041012 (2018) | Download Citation




We aimed to identify the cause of disease in patients suffering from a distinctive, atypical form of Usher syndrome.


Whole-exome and genome sequencing were performed in five patients from three families of Yemenite Jewish origin, suffering from distinctive retinal degeneration phenotype and sensorineural hearing loss. Functional analysis of the wild-type and mutant proteins was performed in human fibrosarcoma cells.


We identified a homozygous founder missense variant, c.133G>T (p.D45Y) in arylsulfatase G (ARSG). All patients shared a distinctive retinal phenotype with ring-shaped atrophy along the arcades engirdling the fovea, resulting in ring scotoma. In addition, patients developed moderate to severe sensorineural hearing loss. Both vision and hearing loss appeared around the age of 40 years. The identified variant affected a fully conserved amino acid that is part of the catalytic site of the enzyme. Functional analysis of the wild-type and mutant proteins showed no basal activity of p.D45Y.


Homozygosity for ARSG-p.D45Y in humans leads to protein dysfunction, causing an atypical combination of late-onset Usher syndrome. Although there is no evidence for generalized clinical manifestations of lysosomal storage diseases in this set of patients, we cannot rule out the possibility that mild and late-onset symptoms may appear.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Boughman JA, Vernon M, Shaver KA. Usher syndrome: definition and estimate of prevalence from two high-risk populations. J Chronic Dis 1983;36:595–603.

  2. 2

    Rosenberg T, Haim M, Hauch AM, Parving A. The prevalence of Usher syndrome and other retinal dystrophy-hearing impairment associations. Clin Genet 1997;51:314–321.

  3. 3

    Kimberling WJ, Hildebrand MS, Shearer AE et al. Frequency of Usher syndrome in two pediatric populations: implications for genetic screening of deaf and hard of hearing children. Genet Med. 2010;12:512–516.

  4. 4

    Khateb S, Zelinger L, Mizrahi-Meissonnier L et al. A homozygous nonsense CEP250 mutation combined with a heterozygous nonsense C2orf71 mutation is associated with atypical Usher syndrome. J Med Genet 2014;51:460–469.

  5. 5

    Bashir R, Fatima A, Naz S. A frameshift mutation in SANS results in atypical Usher syndrome. Clin Genet 2010;78:601–603.

  6. 6

    Liu XZ, Hope C, Walsh J et al. Mutations in the myosin VIIA gene cause a wide phenotypic spectrum, including atypical Usher syndrome. Am J Hum Genet 1998;63:909–912.

  7. 7

    Pierrache LHM, Kimchi A, Ratnapriya R et al. Whole-exome sequencing identifies biallelic IDH3A variants as a cause of retinitis pigmentosa accompanied by pseudocoloboma. Ophthalmology 2017;124:992–1003.

  8. 8

    Gong B, Wei B, Huang L et al. Exome sequencing identified a recessive RDH12 mutation in a family with severe early-onset retinitis pigmentosa. J Ophthalmol 20152015: 942740.

  9. 9

    Nishiguchi KM, Tearle RG, Liu YP et al. Whole genome sequencing in patients with retinitis pigmentosa reveals pathogenic DNA structural changes and NEK2 as a new disease gene. Proc Natl Acad Sci USA 2013;110:16139–16144.

  10. 10

    Carss KJ, Arno G, Erwood M et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. Am J Hum Genet 2017;100:75–90.

  11. 11

    Kremer H, van Wijk E, Marker T, Wolfrum U, Roepman R. Usher syndrome: molecular links of pathogenesis, proteins and pathways. Hum Mol Genet 2006;15 Spec No 2:R262–270.

  12. 12

    Reiners J, Nagel-Wolfrum K, Jurgens K, Marker T, Wolfrum U. Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res 2006;83:97–119.

  13. 13

    El-Amraoui A, Petit C. The retinal phenotype of Usher syndrome: pathophysiological insights from animal models. C R Biol 2014;337:167–177.

  14. 14

    Flanagan AM, Stavenschi E, Basavaraju S, Gaboriau D, Hoey DA, Morrison CG. Centriole splitting caused by loss of the centrosomal linker protein C-NAP1 reduces centriolar satellite density and impedes centrosome amplification. Mol Biol Cell 2017;28:736–745.

  15. 15

    Frese MA, Schulz S, Dierks T. Arylsulfatase G, a novel lysosomal sulfatase. J Biol Chem 2008;283:11388–11395.

  16. 16

    Kowalewski B, Lubke T, Kollmann K et al. Molecular characterization of arylsulfatase G: expression, processing, glycosylation, transport, and activity. J Biol Chem 2014;289:27992–28005.

  17. 17

    Beryozkin A, Shevah E, Kimchi A et al. Whole exome sequencing reveals mutations in known retinal disease genes in 33 out of 68 Israeli families with inherited retinopathies. Sci Rep 2015;5:13187.

  18. 18

    Ferrante P, Messali S, Meroni G, Ballabio A. Molecular and biochemical characterisation of a novel sulphatase gene: arylsulfatase G (ARSG). Eur J Hum Genet 2002;10:813–818.

  19. 19

    Waldow A, Schmidt B, Dierks T, von Bulow R, von Figura K. Amino acid residues forming the active site of arylsulfatase A. Role in catalytic activity and substrate binding. J Biol Chem 1999;274:12284–12288.

  20. 20

    Beesley CE, Young EP, Vellodi A, Winchester BG. Mutational analysis of Sanfilippo syndrome type A (MPS IIIA): identification of 13 novel mutations. J Med Genet 2000;37:704–707.

  21. 21

    Morrone A, Tylee KL, Al-Sayed M et al. Molecular testing of 163 patients with Morquio A (mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol Genet Metab 2014;112:160–170.

  22. 22

    Schmidt B, Selmer T, Ingendoh A, von Figura K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 1995;82:271–278.

  23. 23

    Boltes I, Czapinska H, Kahnert A et al. 1.3 A structure of arylsulfatase from Pseudomonas aeruginosa establishes the catalytic mechanism of sulfate ester cleavage in the sulfatase family. Structure 2001;9:483–491.

  24. 24

    Chruszcz M, Laidler P, Monkiewicz M, Ortlund E, Lebioda L, Lewinski K. Crystal structure of a covalent intermediate of endogenous human arylsulfatase A. J Inorg Biochem 2003;96:386–392.

  25. 25

    Dierks T, Schmidt B, Borissenko LV et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell 2003;113:435–444.

  26. 26

    Dierks T, Lecca MR, Schlotterhose P, Schmidt B, von Figura K. Sequence determinants directing conversion of cysteine to formylglycine in eukaryotic sulfatases. EMBO J 1999;18:2084–2091.

  27. 27

    Daniele A, Di Natale P. Heparan N-sulfatase: cysteine 70 plays a role in the enzyme catalysis and processing. FEBS Lett 2001;505:445–448.

  28. 28

    Millat G, Froissart R, Maire I, Bozon D. Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue. Biochem J. 1997;326(Pt 1):243–247.

  29. 29

    Van Hoof F, Hers HG. The abnormalities of lysosomal enzymes in mucopolysaccharidoses. Eur J Biochem 1968;7:34–44.

  30. 30

    Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010;285:20423–20427.

  31. 31

    Abitbol M, Thibaud JL, Olby NJ et al. A canine arylsulfatase G (ARSG) mutation leading to a sulfatase deficiency is associated with neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 2010;107:14775–14780.

  32. 32

    Kowalewski B, Heimann P, Ortkras T et al. Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III). Hum Mol Genet 2015;24:1856–1868.

  33. 33

    Kowalewski B, Lamanna WC, Lawrence R et al. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Proc Natl Acad Sci USA 2012;109:10310–10315.

  34. 34

    Kruszewski K, Lullmann-Rauch R, Dierks T, Bartsch U, Damme M. Degeneration of photoreceptor cells in arylsulfatase G-deficient mice. Invest Ophthalmol Vis Sci 2016;57:1120–1131.

  35. 35

    Kousi M, Siintola E, Dvorakova L et al. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain 2009;132(Pt 3):810–819.

  36. 36

    Wraith JEMucopolysaccharidoses and oligosaccharidoses. In: Fernandes J, Saudubray JM, van den Berghe G, Walter JH(eds). Inborn Metabolic Diseases. Diagnosis and Treatment. Vol 4. Springer: Heidelberg, Germany, 2006: 496–507.

  37. 37

    Khan KN, El-Asrag ME, Ku CA et al. Specific alleles of CLN7/MFSD8, a protein that localizes to photoreceptor synaptic terminals, cause a spectrum of nonsyndromic retinal dystrophy. Invest Ophthalmol Vis Sci 2017;58:2906–2914.

  38. 38

    Roosing S, van den Born LI, Sangermano R et al. Mutations in MFSD8, encoding a lysosomal membrane protein, are associated with nonsyndromic autosomal recessive macular dystrophy. Ophthalmology 2015;122:170–179.

  39. 39

    Haer-Wigman L, Newman H, Leibu R et al. Non-syndromic retinitis pigmentosa due to mutations in the mucopolysaccharidosis type IIIC gene, heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT). Hum Mol Genet 2015;24:3742–3751.

  40. 40

    Giugliani RThe mucopolysaccharidoses. In: Metha A, Winchester B(eds). Lysosomal Storage Disorders: A Practical Guide. John Wiley: Chichester, UK, 2012: 94–100.

Download references


This study was financially supported by the Foundation Fighting Blindness USA (BR-GE-0214-0639 to D.S., E.B., and T.B.-Y.), Israel Science Foundation (2154/15 to S.K.), Chief Scientist Office of the Israeli Ministry of Health and the Lirot association (300009177 to S.K. and 300011893 to D.S. and T.B.-Y.), the Yedidut Research Grant (to E.B.), the Deutsche Forschungsgemeinschaft (DI 575/10-1 to T.D.), and the Swiss National Science Foundation (156260 to C.R.). The authors thank all patients and family members for their participation in this study, and Torben Lübke for critically reading the manuscript. Geto Mengisto, Kerstin Fentker and Mai-Britt Ilse, Inbar Erdinest, and Devora Marks-Ohana are acknowledged for expert technical assistance.

Author information


  1. Department of Ophthalmology, Hadassah–Hebrew University Medical Center, Jerusalem, Israel

    • Samer Khateb MD, PhD
    • , Netta Pollack BSc
    • , Alexey Obolensky PhD
    • , Eyal Banin MD, PhD
    •  & Dror Sharon PhD
  2. Department of Chemistry, Biochemistry I, Bielefeld University, Bielefeld, Germany

    • Björn Kowalewski PhD
    •  & Thomas Dierks PhD
  3. Department of Computational Biology, Unit of Medical Genetics, University of Lausanne, Lausanne, Switzerland

    • Nicola Bedoni MSc
    •  & Carlo Rivolta PhD
  4. Department of Biochemistry, University of Kiel, Kiel, Germany

    • Markus Damme PhD
  5. Monique and Jacques Roboh Department of Genetic Research and the Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    • Ann Saada PhD
  6. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

    • Tamar Ben-Yosef PhD
  7. Department of Otolaryngology—Head and Neck Surgery, Hadassah–Hebrew University Medical Center, Jerusalem, Israel

    • Menachem Gross MD
  8. Department of Genetics and Genome Biology, University of Leicester, Leicester, UK

    • Carlo Rivolta PhD


  1. Search for Samer Khateb MD, PhD in:

  2. Search for Björn Kowalewski PhD in:

  3. Search for Nicola Bedoni MSc in:

  4. Search for Markus Damme PhD in:

  5. Search for Netta Pollack BSc in:

  6. Search for Ann Saada PhD in:

  7. Search for Alexey Obolensky PhD in:

  8. Search for Tamar Ben-Yosef PhD in:

  9. Search for Menachem Gross MD in:

  10. Search for Thomas Dierks PhD in:

  11. Search for Eyal Banin MD, PhD in:

  12. Search for Carlo Rivolta PhD in:

  13. Search for Dror Sharon PhD in:


The authors declare no conflict of interest

Corresponding authors

Correspondence to Thomas Dierks PhD or Eyal Banin MD, PhD or Carlo Rivolta PhD or Dror Sharon PhD.

Electronic supplementary material

About this article

Publication history